Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
6(85.7%)
Phase 1
1(14.3%)
7Total
N/A(6)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06813820Not ApplicableRecruiting

RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial

Role: lead

NCT03845127Not ApplicableWithdrawn

Randomized Evaluation and Verification of Ventricular Enhancement

Role: lead

NCT05710042Unknown

ALIVE Expended Access - Clinical Study

Role: lead

NCT02931240Not ApplicableActive Not Recruiting

BioVentrix Revivent TC™ System Clinical Study

Role: lead

NCT00326690Not ApplicableWithdrawn

Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity

Role: lead

NCT02553785Phase 1Completed

Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy

Role: lead

NCT01568138Not ApplicableCompleted

Prospective Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy

Role: lead

NCT01568164Not ApplicableCompleted

Safety and Efficacy Study of the BioVentrix PliCath HF System

Role: lead

All 8 trials loaded